Background/Objectives: Baricitinib, a selective JAK1/JAK2 inhibitor, shows therapeutic potential in psoriasis; however, its oral use is associated with systemic adverse effects, encouraging the development of topical formulations.
Paulo Sarango-Granda +6 more
doaj +1 more source
Key Strategies for Improving Psychiatric Home‐Based Care in Spain: A Modified Delphi Study
ABSTRACT Aims This study aimed to identify and prioritize key strategies for improving a psychiatric home‐based care programme, the Crisis Resolution and Home Treatment (CRHT) intervention in Catalonia, Spain. The objective was to incorporate the perspectives of service users, family caregivers and healthcare professionals to guide quality improvement ...
Ana María Besoaín‐Cornejo +4 more
wiley +1 more source
Lipid-Based Formulation of Baricitinib for the Topical Treatment of Psoriasis
Background: Baricitinib, commonly used for autoimmune diseases, is typically administered orally, which can lead to systemic adverse effects. A topical formulation could potentially offer localized therapeutic effects while minimizing these side effects.
Roya Mohammadi-Meyabadi +9 more
doaj +1 more source
Cinètica Química Aplicada a Farmàcia. Curs 2007-2008
Pla docent de l'assignatura Cinètica Química Aplicada a Farmàcia de l'Ensenyament de Farmàcia. Curs acadèmic 2007-2008.
Universitat de Barcelona. Facultat de Farmàcia
core +1 more source
Background Mouse brains can contain specific polyglucosan aggregates known as Periodic Acid-Schiff (PAS)-granules. Generated in astrocytes, these granules increase with age and exhibit neo-epitopes of carbohydrate nature that are recognized by natural ...
Clara Romera +6 more
doaj +1 more source
Guia de l'estudiant 1995-1996. Ensenyament de Farmàcia [PDF]
150 anys de la Facultat de Farmàcia de la Universitat de BarcelonaGuia de l'estudiant de l'Ensenyament de Farmàcia del curs acadèmic 1995 ...
Universitat de Barcelona. Facultat de Farmàcia
core
The Sicilian Web plAtform for Rheumatology Network: complete regional implementation and first-year real-world drug utilisation. [PDF]
Corrao S +7 more
europepmc +1 more source
Correction to: Rational design of lipid-based nanoparticles for targeted anticancer therapies. [PDF]
Arenas-Moreira M +3 more
europepmc +1 more source
[To be or not to be… a generic medicine: is this still a valid indicator of pharmacotherapeutic efficiency?] [PDF]
Montagud Penadés E +3 more
europepmc +1 more source
Correction: Combined ACEI and ARB therapy and ICU mortality in critically ill COVID-19 patients: a retrospective cohort study. [PDF]
Marchant I +6 more
europepmc +1 more source

